Sugi Predict

Sugi Predict / Compounds / SCHEMBL563397

SCHEMBL563397

SCHEMBL563397

CCOC(=O)CC(C[N+](=O)[O-])c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 3/20 0.43
▸ F2 P00734 2/20 0.43
▸ PRSS1 P07477 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPT P10636 6/20 0.40
▸ LMNA P02545 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.39
▸ MMEL1 Q495T6 1/20 0.38
▸ PTGS2 P35354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30947796 0.88 ALDH1A1 (0.41) F10F2PRSS1MAPTLMNA
SCHEMBL6478745 0.88 ALDH1A1 (0.41) F10F2PRSS1MAPTLMNA
SCHEMBL1269548 0.88 F10 (0.44) F10F2PRSS1L3MBTL1MAPT
SCHEMBL21609309 0.85 F10 (0.43) F10F2PRSS1L3MBTL1MAPT
SCHEMBL20475270 0.85 F10 (0.43) F10F2PRSS1L3MBTL1MAPT
SCHEMBL1269119 0.85 F10 (0.43) F10F2PRSS1MAPTLMNA
SCHEMBL30947795 0.85 F10 (0.43) F10F2PRSS1L3MBTL1MAPT
SCHEMBL657923 0.85 MAPT (0.46) F10F2L3MBTL1MAPTLMNA
SCHEMBL15127462 0.84 F10 (0.47) F10F2PRSS1MAPTLMNA
SCHEMBL9294262 0.84 F2 (0.50) F10F2PRSS1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118878638-A Polymyxin compound, pharmaceutical composition and application thereof 云顶新耀医药科技有限公司 2024-11-01 — — CN disclosed
CN-112789287-B Compounds of formula (I) 云顶新耀医药科技有限公司 2024-06-21 — — CN disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 — — US disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 — — US disclosed
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Biopharma SRL (BE) 2012-02-09 — — US disclosed
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Biopharma SRL (BE) 2012-02-09 — — US disclosed
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 — — US disclosed
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 — — US disclosed
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2010-09-02 — — US disclosed
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2010-09-02 — — US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 — — US disclosed
EP-1452524-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-09-01 — — EP disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 — — US disclosed
EP-1447399-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-08-18 — — EP disclosed
US-20040116507-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2004-06-17 — — US disclosed
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2004-05-06 — — US disclosed
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2003-06-26 — — US disclosed
CN-1404469-A 2-oxo-1-pyrrolidine derivatives, preparation method and use thereof UCB SA (BE) 2003-03-19 — — CN disclosed
EP-1265862-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2002-12-18 — — EP disclosed
WO-2001062726-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2001-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 F10 3569/4885F2 1082/4885PRSS1 1654/4885
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES CYP1B1, OGDH, CYP1A2 F10 3569/4885F2 1082/4885PRSS1 1654/4885
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH F10 3603/4885F2 1120/4885PRSS1 1716/4885
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH F10 3658/4885F2 1171/4885PRSS1 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.